Olokizumab for treatment of rheumatoid arthritis

Download in PDF

Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents. The efficacy and favorable safety profile of olokizumab in combination with methotrexate in rheumatoid arthritis patients who had previously failed methotrexate or tumour necrosis factor inhibitors were established in the several international 3 phase clinical trials (CREDO). The authors present two cases of successful olokizumab administration and discuss the indications for its use in patients with rheumatoid arthritis to achieve clinical improvement and to prevent progression of AA-amyloidosis.


To study associations of polymorphic variants of dopamine receptor genes with efficacy and safety parameters of antipsychotics in adolescents with an acute psychotic episode.

Key words

Olokizumab, IL-6 inhibitor, rheumatoid arthritis, AA-amyoloidosis.